Madrigal Pharmaceuticals (MDGL) Change in Acquisitions & Divestments (2011 - 2026)

Madrigal Pharmaceuticals (MDGL) has 16 years of Change in Acquisitions & Divestments data on file, last reported at $353.9 million in Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments rose 20.08% year-over-year to $353.9 million in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 17.13% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 25.49% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $353.9 million, up from $240.1 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for MDGL reached as high as $353.9 million in Q1 2026 and fell as low as $12.0 million in Q1 2023.
• Historically, Change in Acquisitions & Divestments has averaged $175.5 million across 5 years, with a median of $163.8 million in 2024.
• Across the five-year window, Change in Acquisitions & Divestments slumped 87.18% in 2023 and surged 1422.61% in 2024, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $79.2 million in 2022, then soared by 43.69% to $113.8 million in 2023, then soared by 165.75% to $302.4 million in 2024, then dropped by 20.59% to $240.1 million in 2025, then surged by 47.36% to $353.9 million in 2026.
• Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $353.9 million in Q1 2026, $240.1 million in Q4 2025, and $275.1 million in Q3 2025.